This research study is currently not recruiting patients.

XIENCE 90 Study

Brief description of study

The objective of this trial is to evaluate safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary intervention (PCI) with XIENCE.


Clinical Study Identifier: s18-01251
ClinicalTrials.gov Identifier: NCT03218787